Published in Int J Oncol on March 01, 2006
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One (2006) 1.48
Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 1.42
Targeting caspases in cancer therapeutics. Biol Chem (2013) 1.13
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol (2007) 0.99
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer (2006) 0.96
Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol (2009) 0.93
The rationale for targeted therapies in medulloblastoma. Neuro Oncol (2013) 0.92
Sonic hedgehog-induced histone deacetylase activation is required for cerebellar granule precursor hyperplasia in medulloblastoma. PLoS One (2013) 0.91
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer (2013) 0.87
REST is a novel prognostic factor and therapeutic target for medulloblastoma. Mol Cancer Ther (2012) 0.85
Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer (2006) 0.83
The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells. Childs Nerv Syst (2011) 0.79
Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. PLoS One (2012) 0.78
Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells. J Cancer Res Clin Oncol (2007) 0.78
Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. Cancer Biol Ther (2016) 0.75
Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists. Childs Nerv Syst (2015) 0.75
Determinants of antileukemia effects of allogeneic NK cells. J Immunol (2004) 2.85
Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood (2004) 2.62
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet (2012) 2.02
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood (2013) 1.65
High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood (2010) 1.60
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leuk Res (2013) 1.58
Outcome of allogeneic stem cell transplantation in children with non-malignant diseases. Haematologica (2006) 1.47
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol (2004) 1.39
Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol (2005) 1.35
Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis (2004) 1.30
CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica (2010) 1.30
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant (2010) 1.23
Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant (2009) 1.21
IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA. Eur J Immunol (2010) 1.20
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One (2013) 1.17
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood (2011) 1.16
IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother (2010) 1.11
Comprehensive phenotypic characterization of human adipose-derived stromal/stem cells and their subsets by a high throughput technology. Stem Cells Dev (2012) 1.10
Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica (2010) 1.06
Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol (2005) 1.04
The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy (2011) 1.04
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett (2008) 1.02
Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Haematol (2004) 1.00
Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol (2003) 1.00
G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides (2006) 0.99
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol (2007) 0.99
Bilirubin measurement for neonates: comparison of 9 frequently used methods. Pediatrics (2006) 0.99
Identification of a novel class of human adherent CD34- stem cells that give rise to SCID-repopulating cells. Blood (2002) 0.98
Safety and efficacy of gravitational shunt valves in patients with idiopathic normal pressure hydrocephalus: a pragmatic, randomised, open label, multicentre trial (SVASONA). J Neurol Neurosurg Psychiatry (2013) 0.97
Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol (2013) 0.97
IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study. PLoS One (2011) 0.97
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer (2006) 0.96
Peroxiredoxin III protects pancreatic ß cells from apoptosis. J Endocrinol (2010) 0.95
Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res (2009) 0.95
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood (2007) 0.95
Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia. Br J Haematol (2005) 0.93
Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis (2007) 0.93
Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial. Auris Nasus Larynx (2010) 0.93
Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging (2010) 0.93
Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression. Haematologica (2013) 0.92
Expression of opioid receptor subtypes and their ligands in fibrillating human atria. Pacing Clin Electrophysiol (2005) 0.92
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant (2010) 0.91
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther (2007) 0.91
Neuroplasticity of semantic representations for musical instruments in professional musicians. Neuroimage (2011) 0.91
Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children. Biol Blood Marrow Transplant (2005) 0.90
Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models. Front Oncol (2012) 0.90
Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant (2009) 0.90
Adult stem cells as an alternative source of multipotential (pluripotential) cells in regenerative medicine. Curr Stem Cell Res Ther (2009) 0.90
Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood (2002) 0.89
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol (2010) 0.89
Mesenchymal stromal cells derived from CD271(+) bone marrow mononuclear cells exert potent allosuppressive properties. Cytotherapy (2011) 0.88
Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol (2003) 0.88
Haploidentical transplantation for acute lymphoblastic leukemia in childhood. Blood Rev (2004) 0.87
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk Res (2011) 0.87
Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells. Pathol Oncol Res (2007) 0.87
L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Nutr J (2012) 0.87
Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J Immunol Methods (2008) 0.86
Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur J Cancer (2011) 0.85
Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One (2012) 0.85
Risks of mortality in children admitted to the paediatric intensive care unit after haematopoietic stem cell transplantation. Br J Haematol (2003) 0.85
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett (2006) 0.85
Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol Pharmacol (2004) 0.84
Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. Oncol Rep (2008) 0.84
Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant (2013) 0.84
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs (2005) 0.84
Predictors of subsequent overdrainage and clinical outcomes after ventriculoperitoneal shunting for idiopathic normal pressure hydrocephalus. Neurosurgery (2013) 0.84
Severe bullous pemphigoid in an infant--successful treatment with rituximab. Pediatr Dermatol (2008) 0.84
Epigenetic control of differential expression of specific ERG isoforms in acute T-lymphoblastic leukemia. Leuk Res (2008) 0.83
Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs (2010) 0.83
Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunol Immunother (2014) 0.83
Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. Cancer Lett (2004) 0.83
Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. Best Pract Res Clin Haematol (2011) 0.83
Stem cell transplantation for polycythemia vera. Pediatr Blood Cancer (2008) 0.83
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. Oncol Rep (2011) 0.83
Effect of topical 1.25% povidone-iodine eyedrops used for prophylaxis of ophthalmia neonatorum on renal iodine excretion and thyroid-stimulating hormone level. J Pediatr (2006) 0.82
Quantification of T-cell receptor excision circle DNA using fluorescence resonance energy transfer and the LightCycler system. J Immunol Methods (2002) 0.82
Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients. J Hematol Oncol (2014) 0.82
MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia. Leuk Res (2013) 0.82
Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers. PLoS One (2013) 0.82
Primary intestinal aspergillosis after high-dose chemotherapy and autologous stem cell rescue. Pediatr Infect Dis J (2006) 0.82
Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett (2010) 0.82
MALT lymphoma in children: a report from the NHL-BFM Study Group. Pediatr Blood Cancer (2006) 0.81
Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. Best Pract Res Clin Haematol (2011) 0.81
Pediatric apheresis with a novel apheresis device with electronic interface control. Transfusion (2012) 0.81
Treatment of severe disseminated juvenile systemic xanthogranuloma with multiple lesions in the central nervous system. J Pediatr Hematol Oncol (2006) 0.81
Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents. Br J Haematol (2012) 0.80
Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol (2005) 0.79